Aim
===

Glucose is the major energetic source of neural cells. In addition to providing ATP via the glycolytic pathway, glucose provides metabolites that are key to brain activity, such as glutamate and NADPH for lipid and glutathione (GSH) synthesis, as well as recycling of ascorbic acid. This short review will focus on glucose-derived compounds from astrocytes that modulate neurotransmission, in addition to providing energetic and substrate replenishment for brain activity. Glutamate, for example, is the main excitatory neurotransmitter and originates from astroglial glucose, as it is synthetized *de novo* from alpha-ketoglutarate. Two specific astrocyte enzymes, pyruvate carboxylase and glutamine synthetase, are necessary for this process. We will restrict this review to the role of glucose-derived compounds (arising directly from the glycolytic pathway in the cytoplasm of astroglial cells) that modulate synaptic receptors or transporters by binding to them, such as lactate, methylglyoxal, and GSH. Moreover, we will review the regulatory role of uridine diphosphate-*N*-Acetylglucosamine (UDP-GlcNAc), which covalently regulates several astrocyte proteins, including glucose metabolism enzymes and related transcription factors, which in turn modulate synaptic communication.

Introduction
============

Preliminarily, it is important to highlight the importance of astrocytes in the synapse, particularly in glucose metabolism. Although there is no doubt about the significance of blood glucose for brain activity, the mode of entry of glucose to the brain and its cell distribution are still debated (e.g., [@B118]; [@B14]). Once inside the cell, glucose is phosphorylated on carbon 6 by hexokinase (HK), generating glucose-6P, which is converted to fructose-6P via the action of an isomerase. These two compounds (glucose-6P and fructose-6P) are used in at least two different pathways. It is possible to propose a metaphorical "X" intersection of these reactions, as illustrated in Figure [1](#F1){ref-type="fig"}, to describe the destinations of glucose in the neural cells. Glucose-6P can be converted to fructose-6P, but can also be used for glycogen synthesis or in the pentose phosphate pathway (PPP) (left and right arm of the X, respectively). On the other hand, fructose-6P continues through the glycolysis pathway until pyruvate is formed, but can also act as the initial compound in the hexosamine pathway, as represented by the left and right legs of the X, respectively.

![Four intracellular destinations of glucose that suggest an intersection in "X." Glucose enters astrocytes mainly via GLUT1, and neurons mainly via GLUT3 and is trapped by phosphorylation (catalyzed by hexokinase 1, HK1). Afterward, four destinations are possible; these form a crossroads in the shape of an X, where glycogen synthesis and the pentose phosphate pathway (PPP) are the left and right arms of the X, and glycolysis (until pyruvate) and the hexosamine pathway (HP) are the left and right legs of the X. The deviation of glycolysis that generates methylglyoxal (MG) is also indicated. PFK-1, phosphofructokinase-1; G-3P, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate.](fnins-12-01035-g001){#F1}

Glucose Transport and Phosphorylation
-------------------------------------

Before discussing the destinations of glucose, it is important to understand how it enters the neural cells, via the glucose transporter (GLUT) and sodium-glucose co-transporter (SGLT), which are blocked by phloretin and phlorizin, respectively ([@B162]). GLUTs are passive and bidirectional transporters. GLUT1 is the main isoform found in cells forming the blood-tissue barriers (endothelial and choroid plexus), astrocytes and the ependymal cells lining the cerebral ventricles. In addition to glucose, GLUT1 transports dehydroascorbic acid (the oxidized form of vitamin C) ([@B157]) and glucosamine ([@B37]). At the blood-brain barrier (BBB), GLUT1 works at about one-third of maximal capacity under basal conditions ([@B110]). Neurons express mainly GLUT3, although some neurons in the rodent brain also express the insulin-sensitive GLUT4 (in the hippocampus, the cerebellum and the hypothalamus) ([@B35]) and SGLT1 (in the hippocampus and the cerebral cortices) ([@B192]). However, glucose transportation by these carriers is not considered a rate-limiting step in brain energy metabolism. In contrast, the next step, glucose phosphorylation by hexokinase, represents the rate-limiting step.

Notably, more than 90% of non-fenestrated capillary brain vessels are covered by astrocytic end-feet ([@B100]). Moreover, the tight junctions between endothelial cells (responsible for non-fenestration) are actively regulated by astrocyte signals ([@B13]). These aspects indicate the importance of astrocytes in glucose distribution. However, this does not mean that glucose needs to pass through astrocytes to reach neurons. In fact, after crossing endothelial cells via GLUT 1, glucose can reach neurons directly via GLUT3, because there is room for molecular diffusion, since astrocytes form gap junctions among themselves instead of tight junctions.

Glucose phosphorylation on C~6~, catalyzed by HK, is the first rate-limiting step of glycolysis. All three isoforms of HK (of low Km) are present in brain tissue, but HK1 is the most abundant isoform in neurons and astrocytes and it is assumed to be "the brain hexokinase." HKs 1 and 2 bind to the outer mitochondrial membrane by a hydrophobic sequence at their N-terminal, close to the pore that allows ATP output ([@B146]). The activation of Akt kinase (or inhibition of glycogen synthase kinase 3, GSK-3) favors the binding of HK to the mitochondria by a mechanism that is still unclear. Glucose-6P induces a conformational change of the HK, displacing it from the mitochondria and decreasing its activity. Glucose-6P acts as a non-competitive inhibitor of HK, which under basal conditions is predominantly inhibited ([@B47]).

PFK-1 Catalyzes the Other Rate-Limiting Step of Glycolysis
----------------------------------------------------------

Glucose-6P is isomerized to fructose-6P, which in turn is converted to fructose-1,6-bis-phosphate (F1,6BP, see Figure [1](#F1){ref-type="fig"}). This reaction is the second rate-limiting step of glycolysis and is catalyzed by PFK-1. HK has been reported to be higher expressed in neurons than in astrocytes ([@B118]); however, the activity and regulation of PFK-1 in astrocytes suggest a higher glycolytic activity in these cells ([@B23]). PFK-1 is allosterically downregulated by metabolites ATP, citrate and long-chain fatty acids ([@B97]) and upregulated by fructose 2,6 bisphosphate (F2,6BP) ([@B127]). Moreover, lactate, at least in muscle cells, is able to disarrange the tetrameric structure and reduce the enzymatic activity of PFK-1 ([@B42]). F2,6BP, the main allosteric activator, is present in astrocytes at higher concentrations than in neurons. In fact, the enzyme responsible for the generation of F2,6BP from fructose-6P in brain tissue, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB-3), has lower expression levels in neurons due to elevated proteosomal degradation ([@B81]). PFKFB-3 is the target of several kinases, including Akt and AMP-activated protein kinase (AMPK; [@B124]). AMPK is able to phosphorylate/activate PFKFB-3 as well as PFK-1 ([@B16]), indicating a direct regulatory role of AMP.

The lower activities of PFK-1 and PFKFB-3 in neurons suggest that glucose uptake could be conducted to the PPP to generate NADPH, which is required for the regeneration of GSH in these cells ([@B23]). Neurons have low concentrations of GSH ([@B57]) and activity of γ-glutamyl cysteine ligase (GCL; [@B122]) when compared to astrocytes. Interestingly, oxidative stress-mediated S-glutathionylation of PFKFB-3 decreases its catalytic activity in cancer cells, redirecting the glycolytic flux to the PPP ([@B161]). Understanding the metabolic regulation of these three enzymes (HK1, PFK-1, and PFKFB-3) is important for comprehending the journey of glucose to pyruvate (including the passage through glycogen) or to ribulose-5 (PPP), as well as the effects of products of these pathways (lactate, methylglyoxal, and GSH) on synaptic communication. All these regulatory enzymes of glucose flow are direct or indirect targets of GlnNAcylation, which in turn depends on glucose flow itself, as we will discuss below.

The Left Arm and Leg of Glucose Metabolism Modulate Synaptic Transmission Via Lactate
=====================================================================================

Lactate, directly derived from glucose or glycogen (in astrocytes), performs functions beyond energy supply. These functions are mediated by different mechanisms and newly presented pathways (already verified or still proposed), including a specific receptor and its signaling transduction pathways.

The Lactate Receptor: For Every Orphan, a Family
------------------------------------------------

The lactate receptor, initially known as GPR81, belongs to a family of G protein-coupled receptors (GPRs). It was first mapped via a genomic sequence database and then identified in the human pituitary gland ([@B107]). At that time, in the absence of a specific ligand, the receptor was considered an orphan. Later, the receptor was shown to be highly expressed in adipose tissue ([@B116]). The subsequent pharmacological characterization of [L]{.smallcaps}-lactate as a ligand for GPR81 was initiated, taking into account the similarity of GPR81 with other receptors from the GPR family, GPR109a and GPR109b, which also have β-hydroxybutyrate as a ligand. [L]{.smallcaps}-lactate inhibits lipolysis via GPR81 in adipocytes from human, mouse, and rat adipose tissue ([@B30]; [@B116]). The suggestion that lactate may act in a hormone-like manner comes from the demonstration of an insulin-dependent inhibition of lipolysis via GPR81 by [@B2].

As all GPR ligands are hydroxy-carboxylic acids, the GPRs are now HCA receptors (HCARs; [@B1]; [@B21]; [@B137]). GPR89/HCAR1 has received more attention during recent years and has been implicated in inflammation and cancer signaling \[for reviews, see ([@B75]; [@B137])\]. A compound present in fruits ([@B115]; [@B18]), 3,5-dihydroxybenzoic acid (DHBA), was identified as an agonist for HCAR1, inhibiting lipolysis in wild-type mouse adipocytes, but not in HCAR1 knocked-down adipocytes ([@B115]). The HCAR2 ligand 3-hydroxy-butyrate has been considered as an antagonist for the HCA1 receptor and has been used experimentally as such ([@B165]).

To characterize HCAR1 signaling pathways, a study using a cell line designed to express human HCAR1 (CHO-K1) showed activation of extracellular signal-regulated kinases (ERK1/2) via HCAR1 in response to lactate and DHBA and sensitivity to the G~i~ protein inhibitor pertussis toxin ([@B111]). Moreover, the Gαγ subunit dissociated from the activated G~i~ protein was central in the regulation of HCAR1-activated ERK1/2 phosphorylation via extracellular Ca^2+^, protein kinase C (PKC), and insulin-like growth factor-1 receptor (IGF-1R) activation. Arrestin-2 and 3 had no effect on ERK1/2 activation, whereas HCAR1 internalization was dependent on arrestin-3 ([@B111]). Supposed non-canonical actions of the HCAR1 receptor, i.e., without involving cyclic AMP (cAMP) reduction, have been proposed based on β-arrestin actions but still await future confirmation ([@B18]; [@B129]) and a different yet unknown receptor has also been suggested ([@B174]).

[D]{.smallcaps}-lactate, the stereoisomer of [L]{.smallcaps}-lactate, is produced at very low concentrations under physiological conditions from methylglyoxal (MG, see below). It is considered to be a partial agonist of the HCAR1 receptor with maximal stimulation significantly lower than that by [L]{.smallcaps}-lactate ([@B30]). As reported throughout this review, although some studies have shown [D]{.smallcaps}-lactate as a positive control for [L]{.smallcaps}-lactate HCAR1 signaling in neurons ([@B25]), many other studies have shown antagonistic ([@B174]), absent ([@B80]), and controversial actions of the lactate enantiomer on neuroprotection and cognitive functions ([@B69]; [@B32]).

Synaptic and Vascular Modulation by Lactate
-------------------------------------------

The presence of the -- at that time -- orphan GPR81 was first demonstrated in brain tissue in 2001 ([@B107]). HCAR1 is located at synaptic membranes of excitatory synapses in the hippocampus and the cerebellum. It is located predominantly at postsynaptic sites, but it is also present in astroglial end-feet processes and endothelial membranes, indicating that energy metabolism is associated with synaptic function ([@B106]). The vascular endothelial density of the receptor is twice the density at the astrocytic end-feet, suggesting a lactate control of cerebral blood flow (see Figure [2](#F2){ref-type="fig"}). The effect of physical exercise on the density of capillaries via HCAR1 in the sensorimotor cortex and more markedly in the hippocampus, was reproduced by daily subcutaneous injections of [L]{.smallcaps}-lactate (about 10 mM in the blood). The regulation of angiogenesis via HCAR1 and downstream Erk1/2 and Akt signaling resulting in vascular endothelial growth factor (VEGF) production were confirmed by the extensive expression of the receptor at perivascular pial and pericyte-like cells ([@B128]).

![Generation and release of lactate in astrocytes. [L]{.smallcaps}-lactate is generated either from recently uptaken glucose or from glycogen. Neurotransmitters (NT), and/or extracellular K^+^, trigger glycogen breakdown until lactate, via cAMP/PKA signaling. Lactate leaves the cell by the monocarboxylate transporter 1 (MCT1) and enters neurons via the monocarboxylate transporter 2 (MCT2). Extracellular lactate also binds to hydroxy-carboxylic acid receptor 1 (HCAR1), which is found more abundantly in perivascular and post-synaptic membranes. Lactate travels among astrocytes through gap junctions (GJ). PKA, protein kinase A; GP, glycogen phosphorylase; GS, glycogen synthase; PP1, protein phosphatase 1.](fnins-12-01035-g002){#F2}

Even before the deorphanization of the GPR81, several non-metabolic actions of lactate have been reported in neural cells. Lactate increases the action potential frequency of glucose-sensing neurons at the ventromedial hypothalamic nucleus via K~ATP~ and chloride channels ([@B167]). Another study using cortical astrocyte cultures and SH-SY5Y neuronal cells incubated with lactate showed increased brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) expression in astrocytes but not in SH-SY5Y cells. However, the authors centered their discussion only on the energetic aspect of lactate ([@B41]).

The first demonstration of a signaling pathway involving lactate and receptor interaction in the brain was demonstrated by [@B25], who showed that [L]{.smallcaps}-lactate modulated the calcium spike frequency in primary mouse neuron cultures. The authors showed, for the first time, a brain non-energetic effect of [L]{.smallcaps}-lactate via HCAR1, since other metabolic substrates, such as pyruvate or glucose, could not mimic this effect of [L]{.smallcaps}-lactate. In addition, they used the agonist DHBA, reproducing the effects of lactate, and [D]{.smallcaps}-lactate, which has a poor affinity for the monocarboxylate transporter 2 (MCT2) and works as a partial agonist. On the other hand, a non-metabolic astrocyte-neuron signaling modulation by lactate, through a different and unknown mechanism, was demonstrated by [@B174]. This investigation elegantly showed the release of [L]{.smallcaps}-lactate by astrocytes employing *in vitro* optogenetics. They also demonstrated exogenous lactate in cultured and acute brain slices and showed that *in vivo* lactate administration modulates the excitability of noradrenergic neurons from the locus coeruleus. The authors suggested a possible receptor, other than HCAR1, since [D]{.smallcaps}-lactate acted as an inverse agonist and lactate concentrations used were about ten times lower than the IC50 for the G~i~-coupled receptor.

A study revealed [L]{.smallcaps}-lactate upregulation of immediate early genes associated with *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) transmission in neuronal cultures from the mouse neocortex and *in vivo* administration of [L]{.smallcaps}-lactate ([@B187]). Genes such as Arc, c-Fos, and Zif268 had an increased expression after lactate treatment in a range between 2.5 and 20 mM in a time-dependent manner, with a one-hour peak. An energetic effect was excluded after the ineffectiveness of [D]{.smallcaps}-lactate, pyruvate, and glucose in an equicaloric concentration at the same experimental conditions. Moreover, signaling of lactate on these plasticity-related genes was intracellular, since the MCT blocker UK5099 abolished this effect. Interestingly, after longer treatment periods, lactate also stimulated an increase in BDNF expression and the phosphorylation of Erk1/2. The authors showed lactate action via NMDA receptors, but not a specific lactate receptor.

More recently, one study showed the modulation by lactate of the action potential frequency in pyramidal cells from the CA1 region of the hippocampus, under stable energetic conditions. Both lactate and its agonist, DHBA, induced a biphasic modulation in neuronal excitability, inducing reduced excitability at lower concentrations (lactate at 5 mM and DHBA at 0.56 mM), while higher concentrations (lactate at 30 mM and DHBA at 3.1 mM) increased firing frequencies. Use of a neuronal MCT2 blocker did not abolish the lactate effect and neither did [D]{.smallcaps}-lactate alter the firing frequency of the cells; however, G~i~ protein inhibition via pertussis toxin confirmed the effect of lactate via HCA1R ([@B80]).

Lactate release in response to glutamate uptake was described 20 years ago ([@B149]); however, an alternative molecular pathway for lactate efflux, induced by neuronal depolarization has been proposed ([@B36]). A soluble adenylyl cyclase (sAC) sensitive to HCO~3~^-^ is found abundantly expressed in astrocytes and responds to extracellular K^+^ elevation. An increase in cAMP secondary to HCO~3~^-^influx (via HCO~3~^-^/Na^+^ transporter) was observed in cultured astrocytes and in brain slices; furthermore, sAC was found to be responsible for the production and release of lactate as a consequence of the glycogen breakdown coupled with K^+^ increase in astrocytes (see Figure [2](#F2){ref-type="fig"}). As cAMP levels stimulate glycogen breakdown ([@B148]), HCA1 receptor (coupled to G~i~ protein) activation via lactate could mediate glycogenolysis feedback control by lactate in astrocytes.

The lactate response during neurotransmission is fast and independent of the metabolic status or oxygen availability, leading to the observation by [@B169] of a steady-state reservoir of lactate ([@B169]). The synaptic activity and consequent depolarization caused by extracellular K^+^ have been reported to elicit glycogen mobilization ([@B36]) and lactate generation ([@B168]). On the other hand, using a FRET lactate sensor, the group demonstrated that depolarization, via depletion of the astrocytic lactate reservoir in cultured astrocytes, may occur via a non-identified anion channel ([@B169]).

HCAR1-mediated lactate effects have been suggested to be neuroprotective in depression ([@B31]) and cerebral ischemia ([@B20], [@B19]). More recently, in a middle cerebral artery occlusion stroke model, HCAR1 receptor expression was increased in the hippocampus, the cortex, and the striatum after ischemia ([@B32]). Moreover, in hippocampal slices in an oxygen and glucose deprivation model, DHBA and [D]{.smallcaps}-lactate protected the CA1 region from the insult ([@B32]). Although it is not possible to determine the definitive role for HCAR1 in the synaptic communication at this moment, the astrocyte lactate released during glycogenolysis is reportedly crucial for memory consolidation (see [@B82] for review). However, recent data indicate that an aging-associated shift of glycogen metabolism enzyme concentrations, and their localization in astrocytes and neurons, may occur ([@B59]). In addition to its role in synaptic signaling modulation, the astrocytic steady-state reservoir, and the rapid response to depolarization, lactate may act as a gliotransmitter molecule ([@B174]; [@B169]). However, synthesis rather than release should be considered as the limiting step for lactate signaling in the brain ([@B130]).

Methylglyoxal and [D]{.smallcaps}-Lactate Also Affect Neurotransmission
-----------------------------------------------------------------------

Methylglyoxal is a dicarbonyl compound (formula CH~3~C(O)CHO) derived from endogenous and exogenous sources and responsible for most of the glycation reactions in cell metabolism. The endogenous source of MG comes from enzymatic or non-enzymatic reactions of reducing sugars, lipids and amino acids in the cell. The main source of MG synthesis is from aldehydes, which are intermediates of the glycolysis pathway, such as glyceraldehyde 3-phosphate and dihydroxyacetone-phosphate (see Figures [1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}). At physiological or pathological conditions, MG is produced through spontaneous dephosphorylation of dihydroxyacetone-phosphate ([@B7]; [@B132]). Coffee, alcoholic beverages, cigarette smoke and food are all exogenous sources of MG ([@B134]; [@B7]).

Methylglyoxal is also present in different biological materials (tissues, urine, plasma and the cerebrospinal fluid) and its concentration is related to the status of glucose metabolism ([@B134]; [@B7]). It has been suggested that about 0.1--0.4% of the glycolysis pathway results in the formation of MG ([@B101]). More recently, it has been proposed that MG, at physiological levels (μM), acts as an agonist of the γ-aminobutyric acid type A (GABA~A~) receptor and is associated with anxiolytic behavior ([@B48]) and induction of sleep ([@B90]). However, due to the lower levels of MG in the synaptic cleft (compared to those of GABA), it has been proposed that MG has a modulatory effect on GABA~A~ receptors in the extrasynaptic space ([@B175]).

On the other hand, the relationship between GABA~A~ and glucose metabolism (more precisely, glucose uptake) has been investigated over the last 30 years, but findings are not clear and sometimes conflicting ([@B89]; [@B151]; [@B145]). Currently, measurement of glucose metabolism (based on deoxyglucose uptake) is associated with glutamatergic activity, mainly because glutamate is the predominant neurotransmitter. However, other neurotransmitters such as noradrenaline and adenosine, as well as K^+^ itself, released by neuronal activity, modulate energetic metabolism ([@B83]; [@B181]). In this scenario, MG is a glucose-derivative molecule that putatively connects energetic metabolism and the GABAergic system.

Methylglyoxal is metabolized predominantly by the cytoplasmic glyoxalase system, formed by two enzymes, glyoxalases 1 and 2 (GLO1 and 2), which act sequentially. GLO1 depends on GSH. GSH reacts directly with MG and produces hemithioacetal and GLO1 converts this metabolite to S-Lactoylglutathione. Subsequently, this compound is hydrolyzed by GLO2 into [D]{.smallcaps}-lactate and GSH is regenerated (Figure [3](#F3){ref-type="fig"}). Notice that, due to the lower activity of the left leg of the destination of glucose in neurons, it may be assumed that extracellular MG and [D]{.smallcaps}-lactate, as well as [L]{.smallcaps}-lactate, originate predominantly from astroglial cells.

![Generation and release of MG and [D]{.smallcaps}-lactate in astrocytes. Methylglyoxal (MG) is produced from dihydroxyacetone phosphate (DHAP) by a deviation of the glycolytic pathway. MG is condensed with glutathione (GSH) and then, by sequential action of glyoxalases 1 and 2 (GLO1 and 2), generates [D]{.smallcaps}-lactate and recycles GSH. [D]{.smallcaps}-lactate leaves the cell via monocarboxylate transporter 1 (MCT1) but disturbs lactate and pyruvate flows to mitochondria (not illustrated). MG and [D]{.smallcaps}-lactate leave the cell and act on the GABA~A~ receptor and hydroxy-carboxylic acid receptor 1 (HCAR1), respectively. Extrasynaptic GABA~A~ receptors of MG are not illustrated.](fnins-12-01035-g003){#F3}

[D]{.smallcaps}-lactate is oxidized to pyruvate by a D-isomer-specific lactate dehydrogenase (D-LDH; [@B43]). Mitochondrial D-LDH activity in rat brain tissue is about 60% lower than in liver ([@B114]). High levels of [D]{.smallcaps}-lactate inhibit the membrane [L]{.smallcaps}-lactate transport and pyruvate transport to mitochondria in astrocytes ([@B69]) and neurons ([@B158]), which explains the neurotoxicity of this compound. However, a neuroprotective effect of [D]{.smallcaps}-lactate has been proposed in seizures ([@B6]), possibly due to energy impairment. More recently, in addition to confirming the presence D-LDH activity in mouse brain tissue, it was shown that [D]{.smallcaps}-lactate is a partial agonist of HCAR1 ([@B32]).

Astrocyte Dysfunction, MG-Induced Protein Glycation, and Neurodegenerative Diseases
-----------------------------------------------------------------------------------

It is well known that in aging, diabetes mellitus, and neurodegenerative diseases, MG is elevated to sub-millimolar levels, working as a potent glycant agent ([@B170]; [@B120]). Elevated [D]{.smallcaps}-lactate levels from liver metabolism are observed in diabetic animals ([@B104]) and the accumulation of this compound could contribute to memory impairment, dependent on lactate flow ([@B171]). However, when the detoxifying system fails due to a reduction in glyoxalase activity or GSH deficiency, MG and advanced glycation end-products (AGEs) formation increases, but [D]{.smallcaps}-lactate levels can be reduced, as has been observed in endothelial cells ([@B112]).

Methylglyoxal promotes glycation on lipids, nucleic acid and proteins ([@B3]). MG mainly promotes post-translation modifications on proteins by the Maillard reaction on amino acid residues. The most common glycated amino acids are arginine and lysine and consequently the formation of AGEs such as argpyrimidine, hydroimidazolone (MG-H1), Nε-(1-carboxyethyl)-[L]{.smallcaps}-lysine (CEL), and Nε-(1-carboxymethyl)-[L]{.smallcaps}-lysine (CML) adducts, respectively ([@B152]). AGEs are ligands of the receptor for advanced glycation end products (RAGE) and induce inflammation by activation of the nuclear factor κB (NF-κB) pathway in all neural cells ([@B33]; [@B49]).

Elevated MG seems to increase the expression of astrocyte markers (glial fibrillary acidic protein -- GFAP and S100B) and cytokines in astrocyte culture and *in vivo*, leading to astrogliosis and neuroinflammation ([@B38]). However, cognitive impairment has also been reported without changes in classical parameters of astrogliosis ([@B78]). Impairment in glucose flow and/or dysfunction of the glyoxalase system is a common and early event in neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's diseases (PD).

Elevated MG and AGEs levels play a key role in protein misfolding and oxidative stress, and are also involved in AD ([@B7]). The increases in glycation reactions and MG levels are suggested as a possible link in diabetic individuals that develop AD ([@B96]). In different *in vitro* models, MG induced glutamatergic excitotoxicity by promoting glutamate release ([@B10]) and glutamate uptake disturbance ([@B77], [@B79]). Elevated MG and AGEs stimulate apoptosis and reduce neurogenesis as well as neuronal survival in the hippocampus by downregulation of BDNF expression and its signaling pathways ([@B46]; [@B63]; [@B39]). MG is involved in tau hyperphosphorylation through activation of GSK-3β and p38 mitogen-activated protein kinases (p38 MAPK) ([@B113]). Moreover, AGEs and hyperphosphorylated tau are co-localized in the cytoplasm of neurons, possibly contributing to neurofibrillary tangle formation ([@B119]; [@B64]). AGE immunoreactivity has also been observed in amyloid plaques ([@B131]; [@B105]); recently, MG was shown to glycate Lys-16 and Arg-5 residues on β-amyloid, resulting in glycated Aβ ([@B65]). The Aβ-AGE form is more insoluble, neurotoxic and resistant to protease reactions ([@B7]).

In PD, a predictor event is the low activity of neuronal PPP enzymes ([@B60]) and mitochondrial dysfunction ([@B51]; [@B85]), which changes the redox cell status and increases the anaerobic glycolysis pathway and MG formation. In addition, dysregulation of the glyoxalase system ([@B99]) also leads to high MG levels and an increase in glycation reactions. MG reacts directly with dopamine, reducing its concentration and generating the salsolinol-like compound, 1-acetyl-6.7- dihydroxy-1,2,3,4-tetrahydroisoquinoline, which promotes mitochondrial dysfunction ([@B85]). Moreover, the glycation of the N-terminal region of α-synuclein reduces its ability to remain attached to the plasma membrane. In fact, the accumulation of aggregated glycated-α-synuclein in the cytoplasm results in neurotoxic effects on dopaminergic neurons ([@B180]).

The Right Arm Modulates Glutathione Homeostasis and Glutamatergic Neurotransmission
===================================================================================

Glucose metabolism, in addition to producing energy, supports other important functions, for example the generation of reducing equivalents for antioxidant defenses and biosynthetic pathways, in both astrocytes and neurons ([@B121]). The PPP, which constitutes the right arm of the glucose destinations (Figure [1](#F1){ref-type="fig"}), is the main cytosolic source of NADPH and is essential for regeneration of GSH. This pathway decarboxylates glucose-6-phosphate into ribulose-5-phosphate, a precursor for the nucleotide biosynthesis, conserving the redox energy as NADPH. Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme for the PPP (see Figures [4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}), which in the resting brain represents a minor pathway for glucose metabolism ([@B68]; [@B182]; [@B24]). However, under several conditions, for example in response to injury, the PPP can be markedly upregulated ([@B15]; [@B91]; [@B159]) and has demonstrated protective roles because it provides precursors for tissue repair, as well as increases GSH to avoid oxidative stress and neuroinflammation.

![Synthesis and release of GSH in astrocytes. Cystin (cisteinyl-cystein, CC) is uptaken via the xc^-^ exchanger, which releases glutamate. This exchanger is functionally coupled to the Na^+^- dependent glutamate transporters, GLAST or GLT-1. Cystin is reduced by GSH to two cysteines. The gamma acid group of glutamate then condenses with the amine group of cysteine, forming gamma-glutamyl-cysteine (γ Glu-Cys), by the action of the glutamate cysteine ligase (GCL). Addition of glycine completes the synthesis of GSH that, in part, is exported to modulate ionotropic receptors and as a source of cysteine for GSH synthesis in neurons. The extracellular cysteine from astroglial GSH is generated after sequential action of the extracellular peptidases, γGT and APN. Neurons synthesize low levels of GSH compared with astrocytes, but exhibit a high capacity of GSH regeneration, which depends on NADPH synthesis in the PPP. γGT, gamma peptidyl transpeptidase; APN, aminopeptidase neuronal; GPx, glutathione peroxidase; GR, glutathione reductase; EAAC, excitatory amino acid carrier.](fnins-12-01035-g004){#F4}

In astrocytes, the PPP is essential for maintaining an adequate pool of reduced GSH, since these cells export this antioxidant molecule to neurons. Activation of the PPP in astrocytes protects neurons from oxidative stress by increasing astrocytic GSH levels ([@B173]). In neurons, the low expression of PFKFB-3 (Figure [6](#F6){ref-type="fig"}) results in a low glycolytic rate, and glucose is diverted to the PPP ([@B4]; [@B81]). This is particularly important for generating GSH, since neuronal cells have a lower synthesis and, consequently, GSH concentrations, compared to astrocytes ([@B122]; [@B57]).

Glutathione is an essential molecule for cellular antioxidant defense and detoxification processes, conferring neuroprotection ([@B53]; [@B54]; [@B103]). Impaired GSH metabolism is associated with oxidative stress and inflammatory responses, which have been linked to cerebral diseases and neurodegeneration ([@B52]; [@B108]; [@B8]; [@B11]). An age-dependent reduction in resting NADPH concentration, accompanied by a decrease in GSH levels, has been reported in cultured neurons, making them more susceptible to glutamate exposure ([@B142]). This impaired reducing power can lead to pathological aging, since the inability of neurons to regenerate GSH is a hallmark of AD and PD ([@B44]).

Glutathione is a tripeptide, consisting of glutamate, cysteine and glycine, that is synthesized by two enzymatic steps. First, GCL catalyzes the reaction between glutamate and cysteine to form the dipeptide γ-glutamylcysteine. The second step is the reaction of GSH synthase, which mediates the addition of glycine to γ-glutamylcysteine to form GSH ([@B117]). While the first step catalyzed by GCL is considered the rate-limiting reaction, the intracellular content of cysteine is the rate-limiting precursor for GSH biosynthesis ([@B72]; Figure [4](#F4){ref-type="fig"}).

Glutathione in the brain is present in both intra- and extracellular compartments and acts as a dynamic buffer of the redox state. Non-enzymatically, GSH is able to react directly with free radicals including superoxide, hydroxyl radical, nitric oxide, peroxynitrite and MG ([@B40]; [@B184]; [@B9]). Moreover, GSH can react with protein thiol groups, leading to a reversible formation of mixed disulfides (S-glutathionylation), which are important for preventing protein oxidation, thus preserving and modulating its functions ([@B70]). GSH also participates in enzymatic reactions, such as those catalyzed by GSH peroxidase (GPx) and glutathione-S-transferase (GST). GPx detoxifies hydrogen peroxides and other endogenous hydroperoxides using GSH as an electron donor. In this reaction, GSH is oxidized to glutathione disulfide (GSSG; [@B54]); GSSG is then reduced back to GSH via glutathione reductase (GR) using NADPH ([@B55]; [@B156]).

The high oxidative metabolic rate can increase mitochondrial reactive oxygen species (ROS) production, rendering the brain vulnerable to oxidative stress. Astrocytes and neurons exhibit differences in GSH metabolism and different mechanisms maintain GSH homeostasis between these cell types. In astroglial cells, the basal levels of GSH are higher than in neuronal cells, showing their pivotal antioxidant role in the central nervous system ([@B57]). Neurons, in turn, depend on astrocytic GSH release for providing extracellular cysteine for their synthesis of GSH (Figure [4](#F4){ref-type="fig"}). As previously mentioned, cysteine is the limiting precursor for synthesis of GSH.

Astrocytes have a Cys-Glu exchanger (system xc^-^) that mediates the uptake of cystine, the bioavailable form of cysteine, in exchange for glutamate ([@B27]; [@B139]). Moreover, they express the glutamate/aspartate transporter GLAST (also known as excitatory amino acid transporter 1, EAAT1 in humans) and glutamate transporter 1 (GLT1, or EAAT2 in humans) ([@B109]), which provide intracellular glutamate for GSH synthesis and for system xc^-^ operation ([@B155]). Importantly, these glutamate transporters also account for the majority of glutamate removal from the synaptic cleft, maintaining extracellular glutamate concentrations low to avoid excitotoxicity ([@B5]; [@B160]). In this regard, system xc^-^ and glutamate transporters are associated with both GSH biosynthesis and modulation of glutamatergic neurotransmission, as xc^-^ mediates glutamate release. Altered function of these transporters can result in GSH depletion and/or, consequently, glutamate excitotoxicity in pathological conditions ([@B154]; [@B190]; [@B26]; [@B178]). At the same time, GLAST/GLT1 are also related to glucose metabolism; as they are sodium-dependent, their activity increases the intracellular sodium concentration, consequently activating the Na^+^/K^+^ ATPase pump, which consumes ATP in astrocytes. ATP, in turn, can be supplied by the glycolytic pathway (for a review, see [@B17]).

Glutamate is also involved in the mechanism by which astrocytes are able to readily release GSH in response to neural activity, to maintain neuronal GSH levels via the astrocyte-neuronal GSH shuttle. In astrocytes, glutamate triggers a cascade of signals that promote the expression of antioxidant genes through activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2), leading to the biosynthesis of GSH ([@B66]; [@B98]; [@B125]). In the extracellular space, GSH can be hydrolyzed by γ-glutamyl transpeptidase forming γ-glutamyl and the dipeptide CysGly. CysGly is, in turn, cleaved by the neuronal aminopeptidase N into cysteine and glycine, which serve as precursors for neuronal GSH synthesis ([@B58], [@B56]; [@B84]; Figure [4](#F4){ref-type="fig"}). Neuronal cells are less capable of importing cystine, but the sodium-dependent excitatory amino acid carrier 1 (EAAC1, also known as EAAT3 in humans) is able to uptake cysteine in addition to glutamate ([@B195]; [@B163]). EAAC1/EAAT3 supplies neurons with the rate-limiting precursor for GSH synthesis, directly influencing their redox homeostasis ([@B147]). Furthermore, EAAC1/EAAT3 acts as a bridge between astrocytic and neuronal GSH metabolism by importing cysteine released from the extracellular breakdown of astrocytic GSH.

Glucose metabolism, GSH synthesis and glutamatergic homeostasis are closely associated processes and share extracellular and intracellular regulatory mechanisms. Among these, the neurotrophic factor BDNF has recently been demonstrated as a key regulator of central energy homeostasis ([@B123]). BDNF increases glucose transport in neurons by inducing the expression of GLUT3 through phosphatidylinositol-3 kinase (PI3K) and Akt kinase ([@B29]). Because of the low neuronal content of PFKFB-3, glucose can be used for the generation of GSH through the PPP. Additionally, BDNF can activate hypoxia-inducible factor-1 (HIF-1) and Nrf2, which are related to the induction of enzymes that participate in glucose metabolism in both astrocytes and neurons. Importantly, Nrf2 regulates G6PD, GCL, GSH synthase, system xc^-^, and EAAC1/EAAT3 ([@B177]; [@B166]; [@B62]; [@B135]), thus facilitating both regeneration and synthesis of GSH.

Experimental data have suggested a role for GSH as a neuromodulator. As a thiol-containing compound, GSH may regulate the redox sites of several ionotropic receptors and ion channels, altering their functional characteristics ([@B71]; [@B141]). In this regard, both GSH and GSSG have been demonstrated to modulate neuronal depolarization, calcium ion influx and second messenger activity ([@B95]; [@B179]) through the glutamatergic receptors NMDA and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA). Such effects appear to be dependent on GSH concentrations. At micromolar levels, GSH is inhibitory via its interaction with glutamate binding sites. In contrast, at millimolar concentrations, GSH activates NMDA receptors by reducing functional thiol groups ([@B95]). Interestingly, as a consequence, GSH becomes oxidized to GSSG, which triggers an increase in the PPP to generate GSH ([@B45]).

In retinal glial cells, GSH induces calcium shifts in a P2X7 (a purinergic receptor subtype), but not ionotropic glutamate receptor dependent manner. In contrast, GSSG did not reproduce this effect, indicating that the antioxidant and/or structural features of GSH are essential to promote elevations in cytoplasmic calcium levels ([@B67]). In cortical brain slices, GSH was able to evoke a depolarizing potential that appears to be mediated by sodium ions. As this potential was not blocked by antagonists of glutamate receptors, GSH may act through its own receptor-mediated channels ([@B164]). In this regard, radioligand binding assays have shown the presence of binding sites for GSH in different neural cell preparations, including brain synaptosomal membranes ([@B93]) and astrocytes ([@B73]). GSH also seems to be released upon calcium-dependent depolarization in brain slices ([@B194]) and is able to modulate the release of neurotransmitters, including GABA ([@B94]; [@B67]) and dopamine ([@B92]). Interestingly, GSH can reverse aging-associated hippocampal synaptic plasticity deficits ([@B189]). Together, these data support an emerging role of GSH in signal transduction and synaptic transmission.

The Right Leg Controls the Other Destinations of Glucose in Neural Cells by Protein Glcnacylation
=================================================================================================

The Protein GlcNAcylation and Hexosamine Pathway
------------------------------------------------

The post-translational modification of proteins by *O*-linked-*N*-acetyl-D-glucosamine (O-GlcNAc) is assumed to be a glucose-responsive mechanism that modulates cellular signaling (see [@B133] for a review). O-GlcNAc rapidly cycles onto the serine or threonine residues of target proteins. This process is equivalent to phosphorylation and occurs via the activity of two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which add and remove GlcNAcetyl, respectively (see Figure [5](#F5){ref-type="fig"}). GlcNAcetyl is derived from the hexosamine biosynthetic pathway (HP), the right leg in our X of metabolic glucose destination. It is estimated that 2--5% of incoming glucose goes to the HP, which has UDP-GlcNAc as its final product, the donor of GlcNAc ([@B140]). In the liver, the levels of O-GlcNAc-modified proteins fluctuate according to the nutrient status, i.e., they are regulated by intracellular concentrations of UDP-GlcNAc that rise with feeding and are increased in diabetes mellitus patients ([@B76]; [@B133]). In the brain, under conditions of hypometabolism of glucose, as observed in AD, the levels of O-GlcNAc-modified proteins are reduced ([@B50]). However, it is necessary to identify specific changes in protein GlcNAcylation to understand particular protein alterations in physiological and pathological conditions. Herein, we will discuss some aspects of HP regulation and specific targets of O-GlcNAcylation in astrocytes, which modulate glucose metabolism and synaptic communication.

![The hexosamine pathway. In panel **A**, the steps of the hexosamine pathway (HP) from frutose-6P to UDP-*N*-acetyl-glucosamine. Notice that glutamine (Gln), Acetyl-CoA and UTP are key substrates in this pathway. The rate-limiting step is catalyzed by glutamine:fructose-6P aminotransferase (GFAT). In panel **B**, a schematic representation of the structural changes during *N*-acetyl-glucosamine synthesis. The first reaction is the amination of fructose-6P (fructofuranose) to glucosamine-6P (glucopyranose). It is worth noting that, in step six, carbon 1 of glucopyranose binds to the hydroxyl of serine or threonine of the protein target. In fact, this is a reaction of *O*-linked β-*N*-acetylglucosaminylation, but for simplification, the nomenclature widely used is O-GlcNAcylation. However, this gives the wrong idea that linking occurs at the acyl group. It would be better to use NAGylation, since NAG is another (and the simplest) abbreviation of *N*-AcetylGlucosamine, found in some polymers. Herein, we will maintain the use of the term "O-GlcNAcylation." Abbreviations: OGT, O-GlcNAc transferase; OGA, O-GlcNAcase; Pr, protein.](fnins-12-01035-g005){#F5}

The first reaction of HP is catalyzed by the glutamine:fructose-6P aminotransferase (GFAT) enzyme. The glutamine transfers the amine group to carbon 2 of fructose-6P, converting it to glucosamine-6P ([@B193]). Note that neurons depend on astroglial glutamine, since glutamine synthetase is a glial enzyme. In the next step, acetyl-CoA transfers acetyl to the amine group and then the phosphate from carbon 6 is transferred to carbon 1. This compound, *N*-acetyl-glucosamine-1P, reacts with UTP to release the end products UDP-GlcNAc and PPi. The rate-limiting step of HP is the reaction catalyzed by GFAT, which is negatively modulated by AMPK ([@B61]), like other glycolytic key enzymes such as PFK-1 and PFKFB-3. Therefore, besides glucose flow, GlcNAcylation of proteins is regulated by GFAT, and also by the activities of OGT and OGA ([@B185]).

The OGT and OGA enzymes are evolutionarily well conserved and have many targets involved in signal transduction, transcription, translation, cell cycle control and apoptosis. However, since these are just two enzymes (in contrast to the hundreds of protein kinases and phosphatases), there is still little understanding of how their targets are recognized ([@B188]). Moreover, Ser and Thr sites for GlcNAcylation and phosphorylation co-exist in the same protein and these modifications often share the same sites, establishing a complex functional relationship ([@B183]; [@B87]).

Glucose Flow Regulates Its Own Fate and Its Derivatives
-------------------------------------------------------

The main protein targets of O-GlcNAcylation, which modulate glucose flow and/or destination, are indicated in Figure [6](#F6){ref-type="fig"}. GFAT, the regulatory enzyme of HP, is inhibited by phosphorylation, catalyzed by AMPK, at Ser 243 ([@B61]). Therefore, activated AMPK decreases UDP-GlcNAc levels. However, AMPK is also able to phosphorylate (activate in this case) the OGT at Thr 444, which in turn could lead to O-GlcNAcylation of AMPK, resulting in a complex regulation that involves changes in the activities of enzymes as well as their cellular localizations ([@B28]). It is possible, but has not yet been determined, that this triangular interaction among AMPK, GFAT, and OGT occurs in neural cells, particularly in astrocytes, where AMPK has a crucial role ([@B22]).

![Regulation of cellular destinations of glucose by O-GlcNAc modification of proteins. AMP-activated protein kinase (AMPK) and protein kinase A (PKA) have a narrow interaction in the regulation of glucose metabolism as well as phosphorylate and are targets of O-GlcNAc transferase (OGT). The phosphorylation of specific targets of AMPK or PKA in the four cellular destinations of glucose are indicated by the respective colored arrows. Targets of OGT are indicated by G. Two transcription factors closely related to glucose metabolism (cMyc and HIF-1α) are represented at the double-strand DNA and five proteins whose expressions are regulated by these transcription factors are indicated. G6PD, glucose-6-phosphate dehydrogenase; GFAT, glutamine:fructose-6P aminotransferase; GLUT1, glucose transporter 1; GP, glycogen phosphorylase; GPK, glycogen phosphorylase kinase; GS, glycogen synthase; GSK, glycogen synthase kinase; HIF-1α, hypoxia-inducible factor-1α; HK1, hexokinase 1; LDH, lactate dehydrogenase; PFK-1, phosphofructokinase 1; PFKFB-3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; SNAT, sodium-neutral amino acid transporter (type 3 or 5, in astrocytes).](fnins-12-01035-g006){#F6}

Glutathione, as discussed above, has an important antioxidant role in neurons. However, at higher concentrations in astrocytes, it is exported not only to support neuronal synthesis, but also to modulate ionotropic synaptic receptors. Glucose generates NADPH in the PPP to recycle GSH in neurons and astrocytes. The G6PD enzyme is the rate-limiting step of this pathway. G6PD is modulated by O-GlcNAcylation, as demonstrated in several cell lines ([@B153]). In contrast to O-GlcNAcylation of GFAT, this modification of G6PD activates the enzyme, increasing the activity of the PPP and NADPH formation. Although this is of importance in neurons to regenerate GSH, the effect of O-GlcNAcylation on neuronal G6PD has not yet been analyzed. However, it is possible to realize the importance of glutamine from astrocytes to neuronal synthesis of glucosamine-6P, the precursor of UDP-GlcNAc. Another important aspect of GSH synthesis, particularly in astrocytes, is its modulation by AMPK ([@B74]). AMPK positively regulates the expression of the modulatory subunit of enzyme GCL through the transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), (Figure [4](#F4){ref-type="fig"}), which catalyzes the first step (and regulatory step) of GSH synthesis.

Glycogen synthase (GS) is covalently modified by phosphorylation (induced by catecholamines and insulin) and O-GlcNAcylation, at least in adipocytes ([@B144]). Phosphorylated GS is less sensitive to the allosteric activator, glucose-6P. Insulin phosphorylates both GSK3 and the glycogen-targeting protein through the PI3K/Akt pathway, in turn activating protein phosphatase 1, PP1. Phosphorylation of both GSK-3 and PP1 activates GS, which leads to glycogen formation ([@B136]). Similarly, glucose flow in the HP leads to O-GlcNAcylation and activation of the GS. This is an example of mutual exclusivity, where O-GlcNAcylation acts similarly to dephosphorylation, which cannot be generalized to other conditions. Moreover, this relationship is more complex because the upstream enzymes, Akt and GSK3, are also targets of O-GlcNAcylation (e.g., [@B143]).

Glycogen breakdown is also regulated by phosphorylation of glycogen-targeting protein by protein kinase A (PKA) at a different site of Akt ([@B12]). This PKA-induced phosphorylation is triggered by neurotransmitters. The resulting phosphorylation of glycogen-targeting protein at the glycogen granule dissociates PP1, glycogen phosphorylase (GP), glycogen phosphorylase kinase (GPK), and GS. PKA phosphorylates/activates GPK, which in turn phosphorylates/activates GP. This dissociation is an important step because both GP and GPK are targets of PP1. Moreover, PKA phosphorylates/activates the inhibitor 1 of PP1. It was recently reported that the catalytic subunit of PKA is a target of O-GlcNAcylation ([@B186]), but the direct effect on glycogen breakdown remains unclear. Interestingly, O-GlcNAc protein modification increases in tumor cells, in response to glucose deprivation, through glycogen degradation ([@B102]), contradicting the idea that an increase in O-GlcNAcylation acts as a negative feed-back signal to ATP generation from glucose. This phenomenon may involve changes in GS/GP balance, due to changes in OGT and/or OGA, and not UDP-GlcNAc levels ([@B176]).

Lactate generation is strongly regulated by O-GlcNAcylation because PFK-1 and PFKFB-3 are direct and indirect targets of OGT, respectively. O-GlcNAc modification of PFK-1 at Ser529 is induced by hypoxia in cancer cells and this modification inhibits enzyme activity and redirects the flux of glucose to PPP ([@B191]). The authors also observed a modest O-GlcNAcylation of HK. PFKFB-3, which regulates PFK-1, is phosphorylated by AMPK and Akt, which are targets of OGT, as mentioned above. Therefore, it is possible to conceive an interaction between AMPK, PFKFB-3, and OGT, that is just as complex or even more than the interaction between AMPK-GFAT-OGT ([@B28]). Moreover, at least two transcription factors that have been well studied in tumor cells and are connected to glycolysis are modified by O-GlcNAcylation: c-Myc and HIF-1α. Akt/c-Myc activation induces expression of GLUT-1, HK 1 and 2, PFK-1, lactate dehydrogenase A and glutamine transporters ([@B126]; [@B172]; [@B196]). HIF-1α induces GLUT-1 and 3, hexokinases, and PFK-1 ([@B34]). Interestingly, also in cancer cells, lactate is able to trigger changes in glutamine uptake and metabolism ([@B150]), which are necessary not only for cell proliferation but also for protein O-GlcNAcylation. Considering the importance of glutamine/glutamate in brain tissue and lactate in neuron/astrocyte communication, it would seem that this mechanism is worthy of investigation in the nervous system.

Finally, the interplay between AMPK and PKA in glucose metabolism should be considered. Microdomains of cAMP have been characterized to explain the localized action of this intracellular messenger, at the membrane or on soluble adenylyl cyclase. cAMP acts on PKA and is inactivated by phosphodiesterase. Both enzymes (PKA and sAC) bind to A-kinase anchoring protein (AKAP; [@B197]; [@B138]). A physical connection between PKA and AMPK, via AKAP, has been proposed in muscle cells, where AMPK phosphorylates AKAP, releasing PKA ([@B86]). In hepatocytes, PKA phosphorylates and reduces AMPK activity ([@B88]). Again, although most data regarding protein O-GlcNAcylation derive from tumor and/or non-neural cells, protein O-GlcNAcylation may also occur in the brain. Therefore, it is possible that a general cross-talk occurs between PKA and AMPK (involving O-GlcNAcylation, because both are targets of OGT) with a role in the metabolic regulation of glucose destination and synaptic plasticity.

Summary
=======

The importance of glucose for brain activity is very clear, since glucose provides ATP and replenishment of substrates, such as glutamate and cholesterol. Additionally, glucose metabolism provides derivatives such as lactate, MG and GSH, which regulate synaptic communication. Herein, we propose an intersection in an "X" that defines the four destinations of glucose in neural cells, where astrocytes work as integrative and modulatory elements in the synaptic communication. Such destinations depend on the metabolic arrangement in each cell type, which in turn depends on the glucose supply and neural activity. Extracellular [L]{.smallcaps}-lactate released by astrocytes, either generated from recently captured glucose or from glycogen, binds to HCAR1, a specific perivascular and post-synaptic receptor, regulating synaptic plasticity. Currently, lactate is being considered as a putative gliotransmitter. MG results from a deviation of the glycolytic pathway and is metabolized to [D]{.smallcaps}-lactate. Both MG and [D]{.smallcaps}-lactate are released and modulate neuronal activity, possibly through GABA~A~ and HCAR1, respectively. The main cellular antioxidant GSH, whose regeneration depends on the PPP, is also released by astrocytes and alters the synaptic response by modulating the redox and non-redox sites of ionotropic receptors and ion channels. O-GlcNAcylation is an important post-translational protein modification for cell signaling, and the glucose flow through the HP regulates the content of UDP-GlcNAc. The levels of UDP-GlcNAc, in part, are determinant for the GlcNAc-modification of proteins, including the proteins that modulate the glucose destinations. As discussed above, glutamine from astrocytes is essential, literally, for the neuronal synthesis of UDP-GlcNAc. Although the coupling between astrocytes and neurons most often addresses the relationship of glutamate or GABA with the glycolytic pathway, we should not forget that other neurotransmitters also modulate glucose metabolism, which then regulates neurotransmission through glycolysis-derived products.
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